AOD9604 Research Guide: Identity, Evidence, and Human Limits

AOD9604 is often compressed into a simple label such as “growth hormone fragment” or “hGH 176-191.” Those labels are useful only if the sequence, experimental material, model, and endpoint stay attached. This guide separates the 16-residue AOD9604 peptide from earlier fragments, grades the preclinical and human evidence independently, and shows which conclusions remain unsupported.

Apex-specific research boundary: Apex Laboratory supplies AOD9604 as a research-use-only chemical reagent for in-vitro and preclinical research. It is not a pharmaceutical formulation, is not for human consumption, and is not represented as a treatment, weight-management product, administration product, or substitute for an approved medicine.

What Is AOD9604?

AOD9604 is a modified peptide derived from the C-terminal region of the 191-residue human growth hormone sequence. Cox et al. (2015) defined the peptide as hGH residues 177-191 with an additional tyrosine at the N-terminus. That gives AOD9604 16 residues while preserving a direct relationship to the final 15 residues of hGH.

Reagent identity

The C-terminal fragment research program predates the AOD9604 name. Ma et al. (1982), including J. Bornstein, studied synthetic peptides corresponding to the hGH C-terminal sequence; that paper’s indexed record carries no abstract, so no quantitative result can be verified. Wu et al. (1993) then reported that synthetic hGH 177-191 matched intact hGH in antilipogenic activity but produced no significant lipolytic effect in rat epididymal fat pads; that paper reports no quantitative endpoint. These papers establish lineage, not identity with every later peptide and not a human outcome.

A molecular name is only the first layer of a study. Researchers also need the actual sequence, counterion and salt state when relevant, analytical identity, purity method, storage history, and experimental model. A result obtained with one historical material should not be assigned automatically to a current lot merely because both use the AOD label.

AOD9604, AOD9401, and hGH 176-191

Three names are repeatedly collapsed online. AOD9401 is the 15-residue fragment corresponding to hGH 177-191. AOD9604 adds an N-terminal tyrosine, making a 16-residue peptide. hGH 176-191 is a widely used shorthand that appears to count a 16-residue segment directly from the parent protein. That shorthand is not a reliable substitute for stating the actual sequence used in an experiment.

Heffernan et al. (2000) and Ng et al. (2000) studied AOD9401 in mouse, rat, and ex-vivo lipid-metabolism systems. By contrast, Ng et al. (2000) explicitly described metabolic studies of AOD9604 in obese Zucker rats. The materials are related, but the evidence lanes must remain separate.

This distinction also prevents a common evidence-transfer error: a mechanistic result from AOD9401 cannot simply fill a gap in AOD9604 data. Related structure may motivate a new experiment, but it is not a substitute for that experiment.

What the Preclinical Evidence Shows

AOD9401 lipid-metabolism studies

Heffernan et al. (2000) gave oral AOD-9401 to C57BL/6J ob/ob mice — saline n=8, AOD-9401 n=10 — for 30 days. Body-weight gain was significantly lower than control from day 16 onward, with no difference in food intake. Ng et al. (2000) treated obese Zucker rats with AOD9401 for 20 days: mean adipocyte diameter fell from 110 to 80 µm and weight gain was reduced, without the insulin resistance or glucose intolerance chronic intact hGH caused in the same model.

These are mouse and rat readouts. They narrowed the research question from full-length hGH to a C-terminal domain; they do not fix an AOD9604 effect size or establish a human response.

Direct AOD9604 animal studies

In the direct AOD9604 lane, Ng et al. (2000) gave obese Zucker rats an oral 500 µg/kg daily dose for 19 days and reported body-weight gain cut by more than 50% (15.8 ± 0.6 g versus 35.6 ± 0.8 g in controls), with euglycemic-clamp testing showing no adverse effect on insulin sensitivity. Heffernan et al. (2001) treated obese ob/ob and lean C57BL/6J mice for 14 days by mini-osmotic pump and measured, in the obese mice, reduced body-weight gain, increased in-vivo fat oxidation and raised plasma glycerol, without hyperglycaemia or suppressed insulin secretion.

Heffernan et al. (2001) dosed obese mice and beta-3 adrenergic receptor knockout mice intraperitoneally for 14 days. AOD9604 reduced body weight and body fat in obese mice and lifted suppressed beta-3 receptor RNA toward lean-mouse levels; in knockout mice those changes did not occur, yet an acute dose still raised energy expenditure and fat oxidation.

Additional reported findings

Every lipolysis figure on this page comes from a mouse, rat, rabbit or isolated-tissue preparation. No published human study reports an AOD9604 lipolysis endpoint, and the fragment literature is not internally uniform on lipolysis.

How Strong Are the Mechanism Claims?

The most defensible mechanism statement is that the AOD fragment program produced model-dependent changes in lipid-metabolism readouts without reproducing the full growth-signaling profile of intact hGH. Heffernan et al. (2001) reported that the modified fragment did not bind the growth hormone receptor or stimulate proliferation in a GH-receptor cell assay. That narrows one pathway; it does not identify a complete alternative.

The beta-3 receptor literature is similarly bounded. In knockout mice, some chronic changes associated with AOD9604 were absent while an acute fat-oxidation response was still observed. The result argues against treating beta-3 adrenergic signaling as the single direct explanation. Receptor expression, downstream adaptation, and a direct molecular target are different questions.

Statements such as “selectively burns fat without GH effects” therefore overstate the record. Published studies measured specific lipid and growth-related endpoints in particular models. They did not prove universal tissue selectivity, a complete safety profile, or a direct target that predicts a human effect.

What Does the Human Evidence Show?

The human evidence is much thinner than the preclinical literature and is not fully available as detailed peer-reviewed reports. Wilding (2004) reviewed AOD-9604 as an investigational metabolic candidate, recording only that phase IIa trials were under way by February 2002; that development note reports no quantitative endpoint of its own. That historical status should not be mistaken for approval or for a positive completed efficacy program.

The FDA’s 2024 Pharmacy Compounding Advisory Committee evidence review summarized several early studies and the larger OPTIONS obesity study. According to the review, OPTIONS enrolled 536 participants and did not find a statistically significant difference between AOD9604 and placebo on the primary weight-loss endpoint. The sponsor ended obesity development in 2007.

That outcome matters more than isolated secondary descriptions because it addresses the development program’s central human question. The same FDA review noted that important study details were unavailable, found no registered AOD9604 studies in its ClinicalTrials.gov search, and concluded that evidence of effectiveness and safety was insufficient for the proposed compounding-list context.

A neutral primary endpoint does not prove that every molecular hypothesis is false. It does mean the historical human evidence does not support presenting AOD9604 as an established weight-loss intervention. No dosing, administration, cycling, or personal use conclusion follows from this evidence review.

What Other Research Lanes Exist?

A separate research lane examined joint-tissue outcomes. Kwon et al. (2015) induced knee osteoarthritis in 32 New Zealand white rabbits by injecting 2 mg collagenase type II twice into each knee, then gave weekly injections of 0.6 mL saline, 6 mg hyaluronic acid, 0.25 mg AOD9604, or 0.25 mg AOD9604 combined with 6 mg hyaluronic acid across weeks 4-7, with cartilage morphology, histopathology and lameness assessed at 8 weeks. Scores were worst under saline and best under the combination, whose lameness period was shortest; the abstract reports group comparisons, not numeric scores. It was a rabbit study and does not establish a clinical joint indication.

Analytical and anti-doping studies form another lane. Cox et al. (2015) validated a urine assay with a 50 pg/mL limit of detection, precision under 20% and 62% recovery, and found six candidate metabolites, the fragment CRSVEGSCG being most stable. Detection chemistry answers identity and metabolite questions; it is not evidence of efficacy or safety.

Keeping these lanes separate makes the research map more useful. A rabbit joint model, an obese-mouse metabolism experiment, a mass-spectrometry method, and a historical human obesity study answer different questions. A broad “AOD9604 research” label should never erase those differences.

Regulatory Status

AOD9604 holds no FDA, EMA, NMPA, MHRA, PMDA, TGA or Health Canada approval, and no marketing authorisation from any other regulatory authority anywhere in the world, for any indication. It was never approved as a weight-loss therapy: the sponsor ended obesity development in 2007, and the FDA’s 2024 review found the evidence of effectiveness and safety insufficient for the compounding nomination it assessed. Cox et al. (2015) record it as banned in sport by the World Anti-Doping Agency. Supplier status is a separate assertion: supplying a research-use-only reagent confers no approval anywhere.

What Can a Current Research Lot Establish?

A current research lot can be assessed for questions such as identity, purity, and specified analytical characteristics. The strength of those conclusions depends on the method, reference standard, system suitability, sample traceability, acceptance criteria, and whether the certificate can be tied to the lot in hand. The Apex COA guide explains how to audit those fields, while the HPLC testing guide separates a chromatographic purity result from molecular identity.

Analytical confirmation does not transfer the historical literature onto the lot. A high HPLC area percentage does not prove biological activity, receptor engagement, human safety, or clinical efficacy. It also does not convert a research reagent into a pharmaceutical formulation. The broader research-grade versus pharmaceutical-grade guide explains that category boundary.

For study design, researchers should predefine the exact material, model, comparator, endpoint, time point, replication plan, and statistical analysis. A useful AOD9604 experiment asks a narrow question that can distinguish a direct AOD9604 observation from an AOD9401 precedent or a general full-length hGH effect.

For qualified laboratory sourcing, review the current AOD9604 research reagent page. Product availability and lot documentation must be rechecked at deployment.

Researchers reviewing neighboring growth-hormone-axis topics can use the growth hormone axis research guide. That cluster context is taxonomic, not evidence that AOD9604 shares the receptor pharmacology of secretagogues or releasing-hormone analogs.

Frequently Asked Questions

What is AOD9604?

AOD9604 is a synthetic 16-residue peptide based on the C-terminal region of human growth hormone. It contains hGH residues 177-191 plus an additional N-terminal tyrosine. It is distinct from the 15-residue fragment AOD9401 and from full-length human growth hormone.

Is AOD9604 the same as hGH 176-191?

Not exactly. The literature defines AOD9604 as an added N-terminal tyrosine followed by hGH residues 177-191. The shorthand hGH 176-191 is common online, but it can hide the difference between source-protein numbering, peptide length, and the modified AOD9604 sequence.

Did AOD9604 produce weight loss in a large human trial?

The FDA’s 2024 evidence review reports that the 536-participant OPTIONS obesity study did not show a statistically significant difference from placebo on its primary weight-loss endpoint. The sponsor later ended obesity development. Publicly available human evidence remains incomplete and does not establish efficacy.

Does AOD9604 work through the growth hormone receptor or beta-3 adrenergic receptor?

Published mouse and cell studies did not support growth-hormone-receptor signaling as the explanation for the measured effects. Beta-3 adrenergic receptor knockout work also showed a more complicated pattern than a direct beta-3 receptor mechanism. A single validated molecular target has not been established.

What can an AOD9604 certificate of analysis establish?

A fit-for-purpose certificate can document the tested lot’s identity, purity, and specified analytical results when methods and records are traceable. It cannot prove that the lot reproduces an animal outcome, establishes human safety or efficacy, or is equivalent to a pharmaceutical product.

References and Primary Sources

1. Ma et al. (1982). Hyperglycaemic action of synthetic peptides related to the C-terminal sequence of human growth hormone.
2. Ng et al. (1990). Effects of exogenous growth hormone on lipid metabolism in the isolated epididymal fat pad of the growth hormone-deficient little mouse.
3. Wu et al. (1993). Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone.
4. Heffernan et al. (2000). Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism.
5. Ng et al. (2000). Molecular and cellular actions of AOD9401 in Zucker fatty rats.
6. Ng et al. (2000). Metabolic studies of AOD9604.
7. Heffernan et al. (2001). Fat oxidation and weight-related endpoints in obese mice.
8. Heffernan et al. (2001). AOD9604 in obese and beta-3 receptor knockout mice.
9. Wilding (2004). AOD-9604 Metabolic.
10. Cox et al. (2015). Detection and in-vitro metabolism of AOD9604.
11. Kwon et al. (2015). AOD9604 in a rabbit osteoarthritis model.
12. FDA (2024). Pharmacy Compounding Advisory Committee review of AOD-9604.
13. PubChem CID 71300630. AOD9604 registry record: CAS number, molecular formula, and molecular weight.
14. UniProt P01241. Human somatotropin sequence record used to confirm hGH residues 177-191.